GSK plc (LON:GSK) Given Consensus Rating of “Hold” by Brokerages

GSK plc (LON:GSK) has been given a consensus rating of “Hold” by the seven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and two have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is GBX 2,034.29.

GSK has been the subject of several research reports. Shore Capital Group reissued a “buy” rating on shares of GSK in a research note on Wednesday, March 25th. Berenberg Bank reaffirmed a “hold” rating and set a GBX 2,000 price target on shares of GSK in a research note on Thursday, March 26th. Jefferies Financial Group reiterated a “buy” rating and issued a GBX 2,500 price target on shares of GSK in a report on Thursday, May 28th. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a GBX 1,900 price objective on shares of GSK in a research report on Monday, June 8th. Finally, Citigroup dropped their price objective on GSK from GBX 2,250 to GBX 2,100 and set a “neutral” rating for the company in a report on Wednesday, May 6th.

GSK Price Performance

Shares of LON:GSK opened at GBX 1,893 on Friday. The company has a quick ratio of 0.73, a current ratio of 0.79 and a debt-to-equity ratio of 106.74. The firm has a market cap of £75.83 billion, a P/E ratio of 13.32, a P/E/G ratio of 1.24 and a beta of 0.30. GSK has a 12 month low of GBX 1,288.61 and a 12 month high of GBX 2,282. The company’s 50-day moving average price is GBX 1,929.23 and its two-hundred day moving average price is GBX 1,987.07.

GSK (LON:GSK) last announced its earnings results on Wednesday, April 29th. The company reported GBX 46.50 earnings per share for the quarter. GSK had a net margin of 17.78% and a return on equity of 35.78%. The company had revenue of GBX 762.90 billion during the quarter. As a group, research analysts forecast that GSK will post 175.980975 EPS for the current fiscal year.

Insider Buying and Selling at GSK

In other GSK news, insider Wendy Becker acquired 4,000 shares of GSK stock in a transaction on Wednesday, April 29th. The shares were purchased at an average cost of GBX 1,963 per share, with a total value of £78,520. Also, insider Jeannie Lee bought 802 shares of the stock in a transaction on Monday, June 22nd. The shares were acquired at an average cost of GBX 5,069 per share, with a total value of £40,653.38. Insiders bought a total of 7,625 shares of company stock valued at $21,347,004 in the last three months. Insiders own 0.20% of the company’s stock.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.